AMD-3100 (AnorMED)

AnorMED is developing AMD-3100, a CXCR4 chemokine receptor antagonist discovered by a collaboration between AnorMED and the Rega Institute, as a potential treatment for HIV infection [337657]. AMD-3100 is a bis-tetraazamacrocycle, which is a potent inhibitor of HIV-1 and HIV-2 viruses. It interacts with the virus-associated uncoating process [172189]. It is currently being evaluated in phase II clinical trials at The John's Hopkins University School of Medicine and two other US sites. The phase II trial will include 20 to 30 patients and is expected to be completed by the middle of 2000 [326272,326832]. In January 2000, analysts at CIBC World Markets predicted a 2003 launch date for AMD-3100, with sales of CAN 43.5 million dollars, rising to CAN 111 million dollars in 2004 [370903].